Reckitt Benckiser, rumored to be eyeing a bid for Pfizer’s OTC unit, is making some big changes to its own consumer health operations.

Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.

Investors and analysts just can’t get enough of pharma breakups—and Allergan may be the next subject of their enthusiasm.

Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.

A new lawsuit alleges that several drugmakers paid bribes in Iraq that helped fuel terrorism.

Ex-Lilly exec Alex Azar may nab the top job at HHS, where he could help pharma navigate some turbulent political waters.

Bristol-Myers aims to get its I-O med Opdivo to cancer patients as early as possible, and a new approval in melanoma would be a step in that direction.

In June, AZ showed its Lynparza had pared down the risk of breast cancer worsening or death 42%. And that showing impressed the FDA.